Site Upgraded to latest version. If any issues please contact us

Personalized Precision Immunotherapy Tested in Brain Tumors


alt

Personalized Precision Immunotherapy Tested in Brain Tumors

In a pilot study in humans, 10 patients with highly malignant glioblastoma brain tumors received a treatment regimen called CAR T cell therapy that reengineers people's own immune cells to recognize cancer-specific proteins. The findings, published July 19 in Science Translational Medicine, could eventually expand the use of CAR T cell-based regimens beyond blood-based cancers like leukemia to solid tumors. "I am firmly convinced that CAR T cells and other immunotherapies have a chance to be a major breakthrough for glioblastoma," said Donald O'Rourke, a professor of neurosurgery at the University of Pennsylvania Perelman School of Medicine and first author on the paper.


By AAAS, USA.


Technology Policy Resource.